A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Actuate Therapeutics Inc.
Bristol-Myers Squibb
AstraZeneca